Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults

NCT02919306 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus

Interventions

BIOLOGICAL: Ad26.Mos.HIV
BIOLOGICAL: MVA-Mosaic
DRUG: Placebo

Sponsor

Janssen Vaccines & Prevention B.V.